It is well established that IL-1α and IL-1β contribute to pro-tumor and anti-tumor mechanisms and have pleiotropic effects on immune cells, angiogenesis, cancer cell proliferation, migration, and metastasis [41,44,45], and therefore there is much controversy over whether or not they should be inhibited in cancer. The gene discussed is IL1B; the disease is cancer.